Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development.

Dubois J, Pizzorno A, Cavanagh MH, Padey B, Nicolas de Lamballerie C, Uyar O, Venable MC, Carbonneau J, Traversier A, Julien T, Lavigne S, Couture C, Lina B, Hamelin MÈ, Terrier O, Rosa-Calatrava M, Boivin G.

Vaccines (Basel). 2019 Oct 30;7(4). pii: E164. doi: 10.3390/vaccines7040164.

2.

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

Mandon ED, Pizzorno A, Traversier A, Champagne A, Hamelin ME, Lina B, Boivin G, Dejean E, Rosa-Calatrava M, Jawhari A.

Vaccine. 2020 Jan 10;38(2):278-287. doi: 10.1016/j.vaccine.2019.10.018. Epub 2019 Oct 18.

PMID:
31630939
3.

Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice.

Lê VB, Dubois J, Couture C, Cavanagh MH, Uyar O, Pizzorno A, Rosa-Calatrava M, Hamelin MÈ, Boivin G.

PLoS Pathog. 2019 Apr 9;15(4):e1007689. doi: 10.1371/journal.ppat.1007689. eCollection 2019 Apr.

4.

Design and Validation with Influenza A Virus of an Aerosol Transmission Chamber for Ferrets.

Turgeon N, Hamelin MÈ, Verreault D, Lévesque A, Rhéaume C, Carbonneau J, Checkmahomed L, Girard M, Boivin G, Duchaine C.

Int J Environ Res Public Health. 2019 Feb 19;16(4). pii: E609. doi: 10.3390/ijerph16040609.

5.

Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.

Pizzorno A, Terrier O, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin ME, Rhéaume C, Croze S, Escuret V, Poissy J, Lina B, Legras-Lachuer C, Textoris J, Boivin G, Rosa-Calatrava M.

Front Immunol. 2019 Jan 29;10:60. doi: 10.3389/fimmu.2019.00060. eCollection 2019.

6.

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.

Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin ME, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F.

NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019.

7.

Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.

Abed Y, Tu V, Carbonneau J, Checkmahomed L, Venable MC, Fage C, Marie-Ève-Hamelin, Dufresne SF, Kobinger G, Boivin G.

Antiviral Res. 2018 Nov;159:26-34. doi: 10.1016/j.antiviral.2018.09.007. Epub 2018 Sep 13.

PMID:
30219318
8.

Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice.

Lê BV, Jandrot-Perrus M, Couture C, Checkmahomed L, Venable MC, Hamelin MÈ, Boivin G.

J Gen Virol. 2018 Oct;99(10):1367-1380. doi: 10.1099/jgv.0.001135. Epub 2018 Aug 10.

PMID:
30102144
9.

Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections.

Lê VB, Riteau B, Alessi MC, Couture C, Jandrot-Perrus M, Rhéaume C, Hamelin MÈ, Boivin G.

Br J Pharmacol. 2018 Jan;175(2):388-403. doi: 10.1111/bph.14084. Epub 2017 Dec 10.

10.

Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia.

Dubois J, Cavanagh MH, Terrier O, Hamelin MÈ, Lina B, Shi R, Rosa-Calatrava M, Boivin G.

J Gen Virol. 2017 Jun;98(6):1174-1180. doi: 10.1099/jgv.0.000796. Epub 2017 Jun 14.

PMID:
28613142
11.

Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.

Ann J, Abed Y, Beaulieu E, Bouhy X, Joly MH, Dubé K, Carbonneau J, Hamelin ME, Mallett C, Boivin G.

Influenza Other Respir Viruses. 2016 Mar;10(2):122-6. doi: 10.1111/irv.12356. Epub 2016 Jan 29.

12.

Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection.

Rogers MB, Song T, Sebra R, Greenbaum BD, Hamelin ME, Fitch A, Twaddle A, Cui L, Holmes EC, Boivin G, Ghedin E.

mBio. 2015 Apr 7;6(2). pii: e02464-14. doi: 10.1128/mBio.02464-14.

13.

Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model.

Aerts L, Cavanagh MH, Dubois J, Carbonneau J, Rhéaume C, Lavigne S, Couture C, Hamelin MÈ, Boivin G.

PLoS One. 2015 Mar 24;10(3):e0120283. doi: 10.1371/journal.pone.0120283. eCollection 2015.

14.

Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines.

Aerts L, Rhéaume C, Carbonneau J, Lavigne S, Couture C, Hamelin MÈ, Boivin G.

J Gen Virol. 2015 Apr;96(Pt 4):767-74. doi: 10.1099/vir.0.000031. Epub 2014 Dec 17.

PMID:
25519171
15.

Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.

Ann J, Samant M, Rheaume C, Dumas C, Beaulieu E, Morasse A, Mallett C, Hamelin ME, Papadopoulou B, Boivin G.

Vaccine. 2014 Sep 29;32(43):5730-9. doi: 10.1016/j.vaccine.2014.08.029. Epub 2014 Aug 27.

PMID:
25173481
16.

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Pizzorno A, Abed Y, Plante PL, Carbonneau J, Baz M, Hamelin MÈ, Corbeil J, Boivin G.

Antimicrob Agents Chemother. 2014 Nov;58(11):6398-405. doi: 10.1128/AAC.02956-14. Epub 2014 Aug 11.

17.

Human metapneumovirus viral load is an important risk factor for disease severity in young children.

Roussy JF, Carbonneau J, Ouakki M, Papenburg J, Hamelin MÈ, De Serres G, Boivin G.

J Clin Virol. 2014 Jun;60(2):133-40. doi: 10.1016/j.jcv.2014.03.001. Epub 2014 Mar 12.

PMID:
24686044
18.

Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk.

Skowronski DM, Hamelin ME, De Serres G, Janjua NZ, Li G, Sabaiduc S, Bouhy X, Couture C, Leung A, Kobasa D, Embury-Hyatt C, de Bruin E, Balshaw R, Lavigne S, Petric M, Koopmans M, Boivin G.

PLoS One. 2014 Jan 27;9(1):e86555. doi: 10.1371/journal.pone.0086555. eCollection 2014.

19.

Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade.

Papenburg J, Carbonneau J, Isabel S, Bergeron MG, Williams JV, De Serres G, Hamelin MÈ, Boivin G.

J Clin Virol. 2013 Nov;58(3):541-7. doi: 10.1016/j.jcv.2013.08.029. Epub 2013 Sep 4.

PMID:
24041471
20.

Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model.

Aerts L, Hamelin MÈ, Rhéaume C, Lavigne S, Couture C, Kim W, Susan-Resiga D, Prat A, Seidah NG, Vergnolle N, Riteau B, Boivin G.

PLoS One. 2013 Aug 28;8(8):e72529. doi: 10.1371/journal.pone.0072529. eCollection 2013.

Supplemental Content

Loading ...
Support Center